In the PIONEER-HF trial, sacubitril/valsartan or enalapril was administered after hemodynamics had been stabilized in acute decompensated heart failure patients, and the effects of the two agents were compared based on NT-proBNP levels. The gene discussed is NPPB; the disease is hydrops fetalis.